Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glafenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glafenine SCHEMBL29438081 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL970807 | 0.99 | CYP1A2 (0.98) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL18309846 | 0.91 | CYP3A4 (0.84) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL18292475 | 0.89 | CYP1A2 (0.81) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL6026546 | 0.89 | HSD17B10 (0.80) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Floctafenine SCHEMBL28086336 | 0.89 | CYP3A4 (0.79) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL11462321 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| Glafenine SCHEMBL8207540 | 0.85 | PTGS1 (0.72) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL21346888 | 0.85 | KDM4E (0.73) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 | |
| SCHEMBL4730108 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP3A4MAPK1HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2913 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240366729-A1 | COMBINATION OF A NURR1 AGONIST WITH AT LEAST ONE OF AN ALDOSTERONE ANTAGONIST, AN INSULIN MODULATOR AND A SULFONYLUREA | GENESIS PHARMA SA (GR) | 2024-11-07 | — | — | US | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| EP-4392033-A1 | COMBINATION OF A NURR1 AGONIST WITH AT LEAST ONE OF AN ALDOSTERONE ANTAGONIST, AN INSULIN MODULATOR AND A SULFONYLUREA | Genesis Pharma SA (GR) | 2024-07-03 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| WO-2024105529-A1 | CHEMICAL DISBUDDING OF LIVESTOCK | MASSEY UNIVERSITY (NZ) | 2024-05-23 | — | — | WO | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| EP-0650361-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | claimed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| US-5051262-A | Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby | ELAN CORP., P.L.C. (IE) | 1991-09-24 | — | — | US | claimed |
| US-4726951-A | New pharmaceutical forms for administration of medicaments by oral route, with programmed release | ELAN CORPORATION P.L.C. (IE) | 1988-02-23 | — | — | US | claimed |
| EP-0123668-B1 | PHARMACEUTICAL COMPOSITION OF GLAFENINE | N.V. SOPAR S.A. (BE) | 1986-10-15 | — | — | EP | claimed |
| EP-0123668-A1 | Pharmaceutical composition of glafenine | N.V. SOPAR S.A. (BE) | 1984-10-31 | — | — | EP | claimed |
| EP-0068954-B1 | PHARMACEUTICAL COMPOSITION WITH ANTALGIC ACTIVITY | PIERRE FABRE S.A. (FR) | 1984-09-26 | — | — | EP | claimed |
| EP-0068954-A1 | Pharmaceutical composition with antalgic activity | PIERRE FABRE S.A. (FR) | 1983-01-05 | — | — | EP | claimed |
| EP-0000678-B1 | INTERMEDIATE FOR SYNTHESIS: GLYCERYLANTHRANILATE AND PROCESS FOR ITS PREPARATION | PIERRE FABRE S.A. (FR) | 1981-08-05 | — | — | EP | claimed |
| EP-0000678-A1 | Intermediate for synthesis: glycerylanthranilate and process for its preparation | PIERRE FABRE S.A. (FR) | 1979-02-07 | — | — | EP | claimed |